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Our goal was to identify the treatment, personal, interpersonal, and hormonal (testosterone) factors in breast
cancer survivors (BCSs) that determine sexual dysfunction. The treatment variables studied were type of surgery, chemotherapy,
radiation, and tamoxifen. The personal, interpersonal, and physiologic factors were depression, body image, age, relationship
distress, and testosterone levels. A sample of 55 female breast cancer survivors seen for routine follow-up appointments from
July 2002 to September 2002 were recruited to complete the Female Sexual Functioning Index (FSFI), Hamilton Depression Inventory
(HDI), Body Image Survey (BIS), Marital Satisfaction Inventory-Revised (MSI-R), a demographic questionnaire, and have a serum
testosterone level drawn. The average time since diagnosis was 4.4 years (SD 3.4 years). No associations were found between
the type of cancer treatment, hormonal levels, and sexual functioning. BCS sexual functioning was significantly poorer than
published normal controls in all areas but desire. The BCSs’ level of relationship distress was the most significant variable affecting
arousal, orgasm, lubrication, satisfaction, and sexual pain. Depression and having traditional role preferences were the most
important determinants of lower sexual desire. BCSs on antidepressants had higher levels of arousal and orgasm dysfunction.
Women who were older had significantly more concerns about vaginal lubrication and pain. Relationship concerns, depression,
and age are important influences in the development of BCS sexual dysfunction. The relationship of testosterone and sexual dys-
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here is growing evidence that women treated for
breast cancer with surgery and chemotherapy com-
monly experience disturbances in sexual functioning.
Over the past 20 years, studies have found that breast
cancer, chemotherapy, or endocrine treatment have had a
negative effect on the sex life of breast cancer survivors
(BCSs) (1–4). Research reveals that sexual problems
among women treated for breast cancer appear to be much
more prevalent when patients have received chemotherapy,
regardless of the type of surgery (5). The most frequent
sexual problems reported have included diminished
sexual desire, decreased arousal and lubrication, painful
intercourse, and inhibited orgasm (6,7). Sexual problems
can occur in patients who have been treated recently and
in patients treated many years before (8). When survivors
finish treatment they begin to realize the lasting impact
that the diagnosis of cancer and it’s subsequent treatment
may have had on their sexual functioning (9–12).
Despite the prevalence of sexual dysfunction among
BCSs, investigators have been unable to identify the most
important relationships between medical treatments and
the patients’ physiological and psychosocial characteristics.
For example, chemotherapy has an adverse impact on the
ovaries’ production of testosterone, which is assumed to
cause a decrease in sexual desire in females. Psychosocial
factors (e.g., mood, relationship quality with partner,
body image) have been assumed to influence the sexual
performance of breast cancer patients, but the evidence is
not definitive. Medical science needs to identify the causes
of different kinds of sexual problems BCSs experience in
order to develop physiological and psychosocial interven-
tions that will help patients and their partners sustain
the quality of their sexual relationship.
Knowing how cancer and its treatment affect sexuality
requires a multidimensional approach. Sexuality is a
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biopsychosocial experience that cannot be explained by
studying patients’ biologic/hormonal, interpersonal, or
psychological experiences alone. Ganz et al. (13) found
that having a new partner, positive mental health, and
good body image explained 33% of the subjects’ level of
sexual interest. Vaginal dryness, having had chemo-
therapy, and having a new partner explained 33% of
the variance in sexual dysfunction, while the quality of the
relationship and the presence of partners’ sexual problems
explained 27% of the sexual satisfaction scores. In their
analysis, the authors demonstrated that sexual function-
ing is not a unitary concept, but one that has different
dimensions that are influenced by medical treatments and
certain personal, physiological, and interpersonal factors.
The purpose of this study was to investigate how
testosterone levels, mood, body image, depression, rela-
tionship quality, and age influence the sexual function of
female BCSs who have been treated with surgery, radi-




A convenience sample of 55 female BCSs who had no
evidence of recurrent disease was studied. Patients were
included if they had completed their initial breast cancer
therapy (surgery, radiation therapy, or chemotherapy). If
the patients had completed their initial therapy but were
continuing on adjuvant hormonal therapy (i.e., tamoxi-
fen), they also were recruited for the study. Patients, irre-
spective of sexual functioning status, were recruited at
well-patient follow-up appointments between July 2002
and September 2002. Recruited BCSs were asked to com-
plete the study questionnaire and provide a blood sample
for testosterone assay. All patients signed an informed
consent form approved by the Human Investigation
Committee. After the informed consent was signed,
each subject had blood drawn, completed the Hamilton
Depression Inventory—Revised (HDI-R), Body Image
Scale (BIS), Female Sexual Functioning Index (FSFI),
Marital Satisfaction Inventory—Revised (MSI-R), and a
demographic questionnaire.
The HDI assesses the severity of physical, cognitive,
and interpersonal symptoms associated with depression.
This 17-item self-report measure assumes a fifth grade
reading level, uses multiple questions to obtain item
scores, and provides a sensitive measure of the severity of
depression. The instrument asks the subject to indicate
how he or she has been feeling over the past 2 weeks. The
instrument has excellent reliability, test-retest reliability,
and validity (14). The manual defines scores above the
94th percentile (a T-score greater than 67, a raw score
greater than 18) as clinically depressed; high scores mean
more severe depression.
The 10-item BIS (15), developed in collaboration with
the European Organization for Research and Treatment
of Cancer (EORTC), is a unidimensional scale used to
measure body image changes in breast cancer patients.
Possible scores range from 0 (good) to 30 (poor).
The MSI-R is a 150-item self-report measure of marital
distress (16). There are 2 validity scales, 1 global distress
scale, and 10 scales that measure specific aspects of the
relationship. The scales measure dissatisfaction with
affection, ability to resolve differences, amount of intimi-
dation or aggression, lack of shared interests, finances,
quality or frequency of the sexual relationship, relation-
ships with the family of origin, role orientation, relation-
ships with their children, and child rearing. A high score
for all scales except role orientation means a high level of
dissatisfaction or distress. A high role orientation score
indicates a strong preference for nontraditional family
roles, where decision making, child care responsibility,
and work outside the home are shared. The MSI-R scale
correlates well with established marital adjustment scales,
differentiates between known healthy and distressed
populations, and distinguishes changes in the distress of
couples in marriage therapy.
Preliminary analysis revealed some MSI-R scales were
highly interrelated. The study sample MSI-R data were
factor analyzed using principal component analysis with
varimax rotation with Kaiser normalization in order to
reduce the number of variables. Three factors were
identified. The first factor included seven scales (global
distress, affective communication, problem-solving
communication, aggression, time together, disagreement
about finances, and sexual dissatisfaction). Three sub-
scales (global distress, affective communication, problem
solving) that had the highest loadings (greater than 0.71)
on the first factor were used to construct a new variable
called relationship distress, used in this study. Relation-
ship distress scores ranged from 2 to 59, with a mean of
17.7 (13.2 SD).
The FSFI (17) is a paper and pencil test that has six
subscales and a summation score that measure subjects’ level
of desire, arousal, lubrication, orgasm, satisfaction, and pain
(dyspareunia). Subscale items are averaged and summed
to get a weighted total score. Scores can range from 2.0 to
36. Higher scores mean better levels of sexual functioning.
Testosterone is an important component of female
sexuality that is thought to influence desire. Surgically








women or women who are receiving estrogen replacement
therapy are likely to experience testosterone deficiency.
Symptoms of testosterone deficiency include loss of libido,
changes in motivation, lack of well-being and persistent
fatigue. Although there is no laboratory definition of testo-
sterone deficiency, testosterone-deficient patients have
sufficient plasma estrogen levels and low circulating
bioavailable testosterone. Current laboratory measures
include total testosterone, sex hormone binding globulin
(SHBG), free androgen index, and dehydroepiandroster-
one sulfate (DHEA-S) level. The biochemical definition of
testosterone deficiency is not well established, but a small
total testosterone/SHBG ratio or free testosterone in the
lower third of the female reproductive range is considered
clinically abnormal (18). Lacking better measures of test-
osterone deficiency for this study, testosterone levels of
the subjects were examined using either free testosterone
or total serum testosterone assays. The normal range for
free testosterone in postmenopausal women is 0.02–0.18





Characteristics of Study Population
 
The sample was predominately well-educated, mar-
ried, white, female BCSs between the ages of 41 and 69
years (Table 1). The average survivor had received treat-
ment 4–8 years prior to the survey. The length of time





 = 42) were in American Joint Committee
Cancer stages I and IIA. Approximately 10% of the sub-
jects in this study were clinically depressed according to
standards in the HDI manual. The average body image
score was high (mean 6.7; SD 7.0).
The means and standard deviations of the subjects’
MSI-R scales were compared with samples used as
“known” groups in the manual. The first “known” sympto-




 = 100) seeking marital ther-
apy. Analysis showed BCSs to be significantly less distressed
than couples in marriage therapy in all areas except
satisfaction with their sexual relationship (Table 2). The
survivors’ concerns about their sexual relationships
were very similar to the level of concern of the couples
in marriage therapy.







Age range 41–69 years
Age (mean ± SD) 53.4 ± 6.6
Education
High school 11 (20.7%)
1–2 years of college 10 (20.7%)
3–4 years of college 9 (15.5%)










Body image score (mean ± SD) 6.7 ± 7.0
Table 2. Comparison of Mean MSI-R Scores for BCSs with Couples in Marital Therapy and Community
Couples (16) Not in Therapya,b
 
MSI-R score BCPs (mean ± SD) (n) Couples in marital therapy (mean ± SD) (n) Matched community (mean ± SD) (n)
Global distress 49.7 ± 8.2 (54) 64.9 ± 6.9*** (100) 47.4 ± 7.8 (154)
Affective communication 50.0 ± 8.2 (54) 61.3 ± 7.7*** (100) 47.6 ± 8.7 (154)
Problem solving 50.3 ± 8.0 (54) 62.5 ± 7.8*** (100) 47.3 ± 9.4* (154)
Aggression 45.8 ± 6.4 (54) 56.9 ± 10.3*** (100) 49.8 ± 9.3** (154)
Time together 48.6 ± 9.4 (54) 60.1 ± 8.2*** (100) 49.1 ± 8.9 (154)
Disagreement about finances 46.3 ± 8.8 (54) 57.4 ± 10.6*** (100) 50.3 ± 8.9** (154)
Sexual dissatisfaction 53.0 ± 10.6 (54) 56.3 ± 10.3 (100) 49.4 ± 9.6* (154)
Role orientation 52.7 ± 9.4 (54)  54.0 ± 7.3 (100) 50.4 ± 9.0 (154)
Family history of distress 50.4 ± 11.2 (54)  54.6 ± 9.6* (100) 49.3 ± 9.3 (154)
Dissatisfaction with children 44.6 ± 8.5 (45) 54.6 ± 11.3*** (78) 49.4 ± 10.1** (122)
Conflict over child rearing 47.0 ± 9.0 (45) 57.9 ± 11.2*** (78) 48.3 ± 7.5 (122)
aFrom the Manual for the Marital Satisfaction Inventory, revised. Western Psychological Services, 1997:58. Reprinted by permission of the publisher and available in chart and transparency 
form from Western Psychological Services, 12031 Wilshire Blvd., Los Angeles, CA, 90025, USA. Not to be reprinted in whole or in part for any additional purpose without the expressed, written 
permission of the publisher. All rights reserved.
bSignificance of mean differences between BCP study sample and respective populations used in validity studies designated by *p = 0.05, **p = 0.01, ***p = 0.001.
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The second known control group was a matched
sample of couples who were not in therapy (Table 2). The





 = 154) in almost all marital satisfaction areas. How-
ever, survivors had significantly greater concerns about
their problem-solving ability and their sexual relationship
than did the normal controls. In summary, the BCS sub-
jects were generally a normal population who were quite
satisfied with their marital relationships but were concerned
about their sexual functioning and problem-solving
processes.
The BCSs in our study were compared with a sample
used in a validity study of the FSFI, a “known” group
of women with sexual arousal disorders seeking ther-
apy (17). Table 3 shows that BCSs were similar to the
“known” symptomatic sexual dysfunction group in their
complaints about decreased desire and sexual pain. How-
ever, the BCSs had significantly poorer sexual functioning
in every area of sexual functioning (desire, arousal, lubri-
cation, orgasm, satisfaction, and pain) than the normal
control group described in the article. Therefore the
survivors in this study had poorer sexual functioning
than normals, but better functioning than women receiv-





Chemotherapy, radiation, mastectomy, lumpectomy,
or tamoxifen were not related to changes in sexual health
as measured by FSFI scores. The impact of any single treat-
ment is unknown because almost all patients had two or




The relative importance of the personal and interper-
sonal variables studied in this study—age, depression,
body image, and quality of their marital relationship
(relationship distress)—on sexual functioning was ana-
lyzed using correlation and multiple regression. Table 4
presents the significant correlations between the ex-





Preliminary analysis revealed that the sexual function-





 = 3) were very low. When the data about these older
women were used, age was the only variable significantly
related to every measure of the dependent variable. When
the oldest were removed, age was only related to the level




Domain Female sexual arousal disorder (mean ± SD) (n) Controls (mean ± SD) (n) BCP (mean ± SD) (n = 55)
Desire 4.7 ± 2.12 (127) 6.9 ± 1.89*** (131) 4.62 ± 2.02
Arousal 9.7 ± 4.78*** (127) 16.8 ± 3.62*** (130)  12.56 ± 5.88
Lubrication 10.9 ± 5.48* (127) 18.6 ± 3.17*** (130)  12.87 ± 6.29
Orgasm 7.1 ± 4.08*** (128) 12.7 ± 3.16*** (129) 9.75 ± 4.85
Satisfaction 8.2 ± 3.59* (127) 12.8 ± 3.03*** (130) 9.58 ± 4.02
Pain 10.1 ± 4.64 (128) 13.9 ± 2.79*** (130)  10.53 ± 5.29
Total weighted score  19.2 ± 6.63** (126) 30.5 ± 5.29*** (129) 22.34 ± 8.9
*p < 0.05, **p < 0.01, ***p < 0.001.
From Rosen R, Brown R, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 
2000;26:191–208. Reproduced by permission of Taylor & Francis, Inc.; http://www.taylorandfrancis.com.
Table 4. Relationship of Variables to Sexual Functioning (Pearson Correlation Coefficient) (n = 55)
 
 
Desire Arousal Lubrication Orgasm Satisfaction Pain Total
Depression −0.31*
Role orientation  0.29*












of sexual pain. Consequently the sample was limited to




Table 4 shows that depression was significantly related








0.31; p < 0.05), even though only
10% of the sample was clinically depressed. Others
(19) too have found that women who are depressed are
more likely to have lower sexual desire. Women who are
not depressed are more likely to have higher desire. In
this study the BCSs’ level of depression was unrelated
to their sexual arousal, lubrication, orgasm, or sexual
pain.
Antidepressants themselves are known (20) to have
undesirable effects on sexual functioning. BCSs in this
study who were on antidepressants had significantly




 = 5.33; p < 0.03)




 = 5.89; p < 0.02) than survivors




Patterns of communication and problem solving are
significantly related to sexual functioning in BCSs. Sur-
vivors who reported more relationship distress (i.e.,
difficulty solving problems, lack of emotional support,
and more general concern about their relationship with
their partners) reported poorer arousal, lubrication,
orgasm, and sexual satisfaction (Table 4). Relationship
distress was not related to the amount of desire or sexual
pain.
In this sample the BCSs’ view of themselves was
related to the level of sexual desire. Women who had
a nontraditional, more equalitarian view of their roles
tended to report higher desire levels than women who
were more traditional. These women tended to have
lower sexual desire scores. The BCSs’ perception of





The BCSs’ perception of their body was significantly




 = 0.65; p < 0.001). Women who
were depressed tended to have a negative image of their
bodies. Body image was related to only one aspect of
sexual function, sexual satisfaction (Table 4). Women
who had a poor body image tended to be more dissatisfied
with their sexual relationship; women who had a better








0.29; p < 0.05). Poor
body image did not appear to affect any other aspect of
sexual functioning. Contrary to the results in other studies
(21), body image was not related to the number of years




In this sample, the level of total serum or free testoster-
one was unrelated to the type or length of cancer treat-
ment, age, or any FSFI sexual dysfunction measure. It is
important to note that 29.8% (13/45) of the BCSs whose
blood was analyzed for free testosterone and 15.4% (2/
13) of BCSs whose blood was analyzed for total serum
testosterone had abnormally low testosterone levels. The
ranges were less than 0.02–0.17 pg/ml (mean 0.04; SD 0.04)




To understand what factors are the best predictors of
sexual functioning, the computed variables relationship
distress, depression, age, and body image were entered
into a linear stepwise multiple regression equation using
each measure of the dependent variable. Relationship dis-
tress (Table 5) explained 16–30% of the variance in BCSs’
arousal, orgasm, satisfaction, and overall sexual function-
ing scores. Relationship distress plus age explained signifi-
cant variance in two measures of sexual functioning, pain
(17%) and lubrication (27%). The degree of depression
and role orientation explained 17% of the variance in
Table 5. Significant Predictorsa of Measures of Sexual Functioning Using Multiple Regression (R2) (n = 55)
 
 
Variable Desire Arousal Lubrication Orgasm Satisfaction Pain Total FSFI






Total variance explained 0.17* 0.16** 0.27*** 0.14** 0.30*** 0.17** 0.16***
aR2 for variables with significance.
*p = 0.05, **p = 0.01, ***p = 0.001.
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sexual desire. Figure 1 illustrates these relationships.
Body image and testosterone did not explain any sig-
nificant portion of the variance in any of the dependent
variable measures.
DISCUSSION
The BCSs in this study had more sexual dysfunction
than the average female population, but were not as dys-
functional as women seeking therapy for sexual disorders.
While historically, practitioners have expected that
certain types of cancer treatments (22–25) will cause
more sexual dysfunction, this study did not support this
hypothesis.
Body image, although correlated with sexual satisfac-
tion, did not explain a significant portion of any variance
in the dependent measures of sexual functioning. This
could have been due to the lack of variance in body image
scores, since most of the BCSs had positive body images.
The analysis of sexual dysfunction in this study
revealed that this construct probably has four dimensions:
desire, physiological responses (arousal, lubrication, and
orgasm), satisfaction, and pain. Each of the four dimen-
sions reacted somewhat differently than the others. Desire
appears to be the most independent, affected by the
woman’s role and depressed feelings. Arousal, lubrica-
tion, and orgasm patterns of responses were very much
alike. Satisfaction is a more general phenomenon, which
apparently does not necessarily include the ability to have
orgasms. Pain and lubrication appear to be very interrelated.
Sexual desire appears to be a dimension of sexuality
that reacts rather independently when women become ill.
Desire may be a psychological phenomenon affected by
the emotional impact of the illness threat, regardless of the
quality of the relationship, body image, or medical treatment.
Knowing that depression is highly related to loss of desire,
physicians need to discuss the impact that depression can
have on the woman herself and her relationship with her
partner (26). Both patients and partners need to know that
during the period of depression and subsequent loss of
sexual desire they need to find alternative strategies for
expressing care and love.
The quality of women’s relationship health appears to
be a stronger predictor of sexual function than the physi-
cal or chemical damage to the body after cancer treatment.
The quality of the relationship appears to be an important
factor in determining BCSs’ sexual function in the physi-
ological processes of arousal-lubrication-orgasm and
satisfaction. Others (27) have found that the sexual
satisfaction of BCSs who can confide in their husbands
and who feel understood was greater than the sexual satis-
faction of women who do not confide in their husbands.
Positive communication, strong problem-solving skills,
and women’s positive feelings about their relationships
appear to decrease the likelihood of sexual dysfunction.
Being able to talk about feelings and concerns and feeling
understood and loved, and being able to find satisfactory
solutions for the problems that cancer brings are important.
Age is related to the amount of lubrication and sexual
pain BCSs experience. The effects of decreased estrogen
secondary to menopause are well documented, especially
the thinning of the vaginal wall and diminished lubrica-
tion, factors associated with painful intercourse. Being
menopausal before cancer treatment increases the chances
of having less lubrication and more sexual pain after treat-
ment. This difference was not explained by a difference in
testosterone levels in pre- and postmenopausal women.
However, in this study, lubrication concerns appear to be
a consequence of age and the quality of the relationship.
Determining whether testosterone has a direct effect on
sexual functioning has been difficult because commercial
assay methods are not particularly sensitive or reliable at
lower hormone levels. Hormone assays provide biological
markers for extreme testosterone deficiencies, but there is
Figure 1. Conceptual Model of Relationship of
Personal and Interpersonal Factors on Sexual
Functioning in Breast Cancer Survivors
(Multiple Regression) (n = 55).
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little information about how or if varying levels of testo-
sterone characterize different types of sexual dysfunction.
This study failed to identify any relationship between
testosterone and sexual dysfunction. Future studies
should include a more sensitive assay of a larger popu-
lation in order to determine if there is an association
between testosterone and sexual dysfunction.
Psychosocial sexual assessments should be included in
the oncology physicians’ standard assessment protocol
and treatment plans (28–30). BCSs who have decreased
desire or arousal, or who have expressed concerns about
their relationship with their partner may profit from coun-
seling or sexual health education early in the course of
their disease. Learning to tell their partner what is sexually
pleasurable and how to communicate and problem solve
more effectively may provide them with better internal
resources for the illness and treatment road ahead.
There are important limitations in this study. The
sample was small and included women who had different
cancer treatments over different lengths of time. Two
methods of assaying testosterone levels were used, making
comparisons impossible. The sample may be unique;
BCSs who agreed to participate may be healthier and more
interested in remaining sexually active than survivors who
refused to participate.
There are measurement problems in sexual functioning
research. According to the authors’ instructions, women
who did not have any sexual activity within the past
month received a zero on more than half of the FSFI items.
The instrument does not solicit information about why
they did not have sex within the last month. A low score
(zero) creates a spuriously low score if the women did not
have sex because they did not have any sexual opportuni-
ties within that month. On the other hand, a zero score
would appear to be appropriate for women who did not
have any solitary or relationship sexual experiences
because of the BCSs’ physical or emotional condition.
Many sexual assessment instruments, including the FSFI,
erroneously assume that sexual functioning is the sum
total of each sexual subscale. Even though subscales are
highly interrelated, adding subscores is inappropriate
because the instrument is not unidimensional. Using the
FSFI total score clouds variations in sexual functioning
and makes pattern analysis, differential diagnosis, and
treatment difficult.
When sexual functioning instruments are used, it is
important to determine how the subjects feel about their
sexual health in order to know whether intervention is
appropriate. Some subjects may not have a high sexual
function score, but may be entirely satisfied. Current sex-
ual function instruments do not include ways to control
for this possibility. In the future, practitioners and
researchers should add a “sexual distress scale” to sexual
functioning assessment tools in order to determine
whether subjects who have sexual dysfunction are dis-
tressed about it and would like to be sexually responsive
(31). Despite these limitations, this study has used stan-
dardized instruments that allow comparisons of BCSs
with normal populations. These analyses have demon-
strated that breast cancer patients do have reduced sexual
function, and that personal and interpersonal factors
influence female sexual response.
The results of this study support the need for further
research on desire, arousal-lubrication-orgasm, satisfac-
tion, and pain in BCSs. For medical interventions to be
effective, physicians must know the cause of sexual dys-
function in BCSs. These causes may be multifactorial,
requiring multiple interventions. Without knowing the
cause, interventions may be ineffective. The identification
of factors that cause sexual dysfunction will help clini-
cians anticipate problems and guide therapy.
Building a predictive model of BCS sexual dysfunction
will require longitudinal study of large samples within
similar age ranges receiving similar treatment regimes.
Since normal physiological changes during a woman’s life
cycle change sexual responsiveness, studies should focus
on women who are either pre- or postmenopausal or
within 10-year age spans.
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